KOD Live signals | Maximize Profits with Getagraph.com

BUY 92083 min ago

@ $4.87

Issued: 14 Feb 2024 @ 13:51

Return: -28.25%

Previous signal: Feb 14 - 09:33

Previous signal: Sell

Return: -1.22 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 13:34):

Stats
Today's Volume	319 946
Average Volume	937 733
Market Cap	183.47M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-1.090 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.700
ATR14	$0.00600 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-30	Baker Bros. Advisors Lp	Buy	40 000	Non-Qualified Stock Options (right to buy)
2023-06-30	Yang Taiyin	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Profusek Robert	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Levy Richard S	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Dahiyat Bassil I	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
96.14
Last 99 transactions
Buy: 3 824 931 \| Sell: 1 385 823

Volume Correlation

Long: 0.03 (neutral)

Short: -0.31 (neutral)

Signal:(53.529) Neutral

Kodiak Sciences Inc Correlation

10 Most Positive Correlations
SONN	0.914
VERU	0.908
VNET	0.908
INFI	0.906
DZSI	0.903
LIVN	0.902
TCX	0.902
RYTM	0.901
PCVX	0.899
FNWB	0.897

10 Most Negative Correlations
TYHT	-0.933
AAON	-0.913
GSHD	-0.912
PLPC	-0.905
ZGNX	-0.903
CNCE	-0.901
LNTH	-0.9
CPTA	-0.897
LMNR	-0.895
ADMS	-0.893

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kodiak Sciences Inc Correlation - Currency/Commodity

-0.15
( neutral )

-0.69
( moderate negative )

0.00
( neutral )

0.36
( neutral )

0.00
( neutral )

0.14
( neutral )

Kodiak Sciences Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-25.95M (0.00 %)
EPS:	$-4.97

Q4	2023
Revenue:	$0
Gross Profit:	$-6.66M (0.00 %)
EPS:	$-1.130

Q3	2023
Revenue:	$0
Gross Profit:	$-6.97M (0.00 %)
EPS:	$-0.950

Q2	2023
Revenue:	$0
Gross Profit:	$-6.66M (0.00 %)
EPS:	$-1.530

Financial Reports:

No articles found.

Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.